Prevalence of Atherosclerotic Cardiovascular Disease (ASCVD) and Diabetes Populations in the United States

Lead Author’s Financial Disclosures: Dr. Gorcyca is an employee of Sanofi. Study Funding: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Background/Synopsis: The American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the management of blood cholesterol recommend statin treatment in patients with ASCVD or diabetes. Guidelines from the National Lipid Association (NLA) recommend achievement of low-density lipoprotein cholesterol (LDL-C) thresholds in these populations. Objective/Purpose: To estimate the prevalence of ASCVD and diabetes populations overall and by disease profiles in the U.S. The secondary aim was to estimate the prevalence of subpopulations treated with lipid lowering therapy (LLT), and achieving LDL-C thresholds of ,70 mg/dL and ,100 mg/dL. Methods: The MarketScan Research Database was utilized with inclusion criteria of 2013 LDL-C measurement (index), age$18 years, and evidence of the following highrisk conditions during two years pre-index: Recent acute coronary syndrome (ACS) within 12 months, stable coronary heart disease (CHD), ischemic stroke, peripheral arterial disease (PAD), or diabetes. The resulting cohort was divided into mutually exclusive strata, which could represent disease profiles such as CHD only, ischemic stroke + diabetes, CHD + PAD + diabetes, etc. Weights by strata were estimated using an optimization algorithm that minimized the difference between the weighted totals for aggregate conditions such as CHD, ischemic stroke, PAD, diabetes and their established national prevalence based on published sources. The methodology ensured the extrapolation accounted for differential weights by disease profiles